Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA
Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.
- Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.
- “EMA's approval paves the way for a comprehensive investigation into the safety and efficacy of a novel therapeutic approach designed to halt or reverse the progression of HCCAA.
- Nacuity is also currently evaluating NPI-001 in Phase 1/2 clinical trials in Australia for retinitis pigmentosa associated with Usher syndrome and cystinosis.
- “Our proprietary NPI-001 has potential to address the myriad diseases and conditions where oxidative stress plays a role.